Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Resistance to antifolates.

Rongbao Zhao1, I David Goldman

  • 1Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.

Oncogene
|October 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biochemistry at scale: Seeing both the forest and the trees.

Trends in biochemical sciences·2026
Same author

Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis.

Nature communications·2026
Same author

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis.

Experimental hematology·2026
Same author

Cerebral Folate Deficiency, Autism, and the Role of Leucovorin.

The New England journal of medicine·2026
Same author

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.

The Journal of clinical investigation·2025
Same author

Mechanistic insights into mutation in the proton-coupled folate transporter (SLC46A1) causing hereditary folate malabsorption.

The Journal of biological chemistry·2025
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
See all related articles

Antifolate drugs are crucial in cancer treatment, but drug resistance can limit their effectiveness. Understanding resistance mechanisms helps develop new therapies and improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Antifolates represent the earliest antimetabolite chemotherapy agents, utilized for over 50 years.
  • Decades of research have elucidated their mechanisms of action and the cellular resistance pathways that emerge.
  • These principles inform the study of resistance to various antineoplastics targeting different cellular mechanisms.

Purpose of the Study:

  • To describe the mechanisms of intrinsic and acquired antifolate resistance.
  • To review strategies for overcoming resistance, including gene therapy for bone marrow protection.
  • To correlate antifolate pharmacology with clinical outcomes in pediatric cancer patients.

Main Methods:

  • Review of existing literature on antifolate mechanisms and resistance.

Related Experiment Videos

  • Analysis of cellular processes involved in drug transport, activation, and degradation.
  • Examination of target enzyme alterations and cofactor pool modulation.
  • Discussion of gene therapy applications and clinical outcome studies.

    • Main Results:

    • Antifolate resistance involves impaired drug uptake/transport, enhanced drug efflux, reduced activation (polyglutamylation), increased drug degradation, target enzyme mutations/overexpression, and altered tetrahydrofolate pools.
    • Gene therapy strategies are being developed to protect normal cells during antifolate treatment.
    • Clinical studies demonstrate a link between methotrexate's cellular pharmacology and treatment outcomes in pediatric cancers.

    Conclusions:

    • Understanding antifolate resistance mechanisms is key to improving cancer chemotherapy.
    • Novel therapeutic strategies, including gene therapy, show promise for enhancing treatment efficacy and safety.
    • Clinical correlation studies are vital for optimizing antifolate-based treatment regimens in pediatric oncology.